logo

Lakes BioScience’s New Biomanufacturing Plant, Ulverston

Closed · United Kingdom · Last reported Mar 2021

Source: Pharmaceutical Technology

Project
Closed

Lakes BioScience is planning to build a pharmaceutical manufacturing plant in Ulverston, Cumbria, UK. The new facility will be built as part of the company’s Project Apex, an initiative to create a customer-focused contract development and manufacturing organisation (CDMO). Pharmaceutical manufacturing facility Ulverston, Cumbria, UK Lakes BioScience 2022 UK-based biopharmaceuticals company Lakes

Status
Closed
Sector
Automotive, Car parking, Commercial, Manufacturing (Industrial), Mass Transit, Warehouse, Rail, Road
Location
United Kingdom
Updated
22 Jul 2026
Source
Pharmaceutical Technology

ConstructChat

Ask ConstructChat about Lakes BioScience’s New Biomanufacturing Plant, Ulverston

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

3 Q
The project “Lakes BioScience’s New Biomanufacturing Plant, Ulverston” is an infrastructure initiative in the Automotive sector, located in United Kingdom. Taiyo aggregates data on it from Pharmaceutical Technology.

Participants

Not available for this record.

Status

Original status

closed

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Lakes BioScience is planning to build a pharmaceutical manufacturing plant in Ulverston, Cumbria, UK. The new facility will be built as part of the company’s Project Apex, an initiative to create a customer-focused contract development and manufacturing organisation (CDMO). Pharmaceutical manufacturing facility Ulverston, Cumbria, UK Lakes BioScience 2022 UK-based biopharmaceuticals company Lakes BioScience is planning to build a pharmaceutical manufacturing plant in Ulverston, Cumbria, UK. The facility will be built as part of the company’s Project Apex, an initiative to create a customer-focused contract development and manufacturing organisation (CDMO). The facility is expected to play a key role in the fight against Covid-19 and any future pandemics. Lakes BioScience will invest £350m ($488m) in developing the plant. Planning permission for groundworks was granted by South Lakeland District Council in February 2021. Another planning application is due to be submitted for above-ground and associated works, with operations at the new site expected to begin in 2022. The biomanufacturing facility will be built on a 3.4ha site owned by multinational pharmaceutical company GlaxoSmithKline (GSK) on Pullman Road, Ulverston. Located close to GSK’s factory in Ulverston, the site is bordered by Pullman Road to the north and a disused railway line to the west. In 2017, GSK scrapped its plans to build a new pharmaceutical plant at the location and committed to donating the disused site to the community for economic development in the region instead. The Lakes BioScience plant is expected to occupy around 10,000m² of space in the middle of the site, surrounded by car parking and landscaping. It will be equipped with 12 units of 2,000l single-use bioreactors, which will help the company to meet an urgent need for manufacturing capability and capacity. The biomanufacturing plant will produce monoclonal antibodies and is expected to generate 250 jobs once complete. Work on the site is due to start in 2021 and the plant is expected to come online within 15 months of ground-breaking. Lakes BioScience is a privately held British pharmaceutical manufacturing firm founded in 2019. Headquartered in Ulverston, Cumbria, the company aims to develop agile, large-scale biopharmaceuticals contract and manufacturing operations in the UK. Lakes BioScience aims to bolster the country’s position in biopharma scientific research, development and manufacturing through its fully digitised facility, incorporating best practices from around the world. The Ulverston facility will boost the UK’s drug manufacturing capability in the wake of the Covid-19 pandemic. The company aims to build on the regional and national capability to manufacture life-changing and life-saving treatments to patients globally, with supply chains currently under huge pressure to manufacture monoclonal antibodies. Lakes BioScience’s new plant is significant because of GSK’s decision to close its cephalosporins manufacturing operations at Ulverston in 2025, unless the GSK plant can be found viable for alternative purposes. UK-based development consultant Quod was contracted for planning the groundworks. The project team includes multi-disciplinary design and engineering companies Arup, BakerHicks and RHDHV, as well as global consultancy and construction firm Mace. Get industry leading news, data and analysis delivered to your inbox Give your business an edge with our leading industry insights.

Original sector

Health

Location

Country

United Kingdom (UK)

Source

Source reliability

High

Source

Pharmaceutical Technology

URL

More Details

Record type

Project

Sector

Automotive, Car parking, Commercial, Manufacturing (Industrial), Mass Transit, Warehouse, Rail, Road

Article published date

2023-08-02

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project